TY - JOUR T1 - NTM模块的初步验证:patient-reported结果测量复合菌群患者肺非结核分枝杆菌病JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01300 -2019欧元六世- 55是汉高皮膜,1 SP - 1901300 AU -艾米丽AU -温斯洛普,凯文·l . AU -牧场,格雷戈里。非盟- Plinke韦斯利盟——Litvin Hana k,非盟- Quittner爆料称非结核分枝杆菌(NTM)导致慢性、衰弱性肺部疾病。患者报告的结果提供了症状、功能和治疗反应的指标。在这里，我们描述了最近开发的NTM模块的初步验证。方法研究人群为西北NTM生物样本库中分离到的禽分枝杆菌复合体(MAC)患者，且符合2007年美国胸科协会/美国传染病学会肺病标准。NTM模块在入学和12个月时进行;一组还完成了生活质量问卷-支气管扩张(QOL-B)。NTM模块生成4个领域分数(0-100;得分越高，功能越好)，反映了NTM特有的症状(NTM症状、身体形象、消化症状和饮食问题)。 We described patient characteristics and mean scores, and evaluated psychometric properties, including response to treatment at 12 months, for each domain.Results Overall, 203 patients with pulmonary MAC disease were included. Average enrolment scores ranged from 76 (NTM Symptoms) to 84 (Eating Problems). Ceiling effects were observed for Body Image (26% of participants) and Eating Problems (52%). Internal consistency (Cronbach's alpha) ranged from 0.67 (Digestive Symptoms) to 0.89 (Eating Problems). The intraclass correlation for test–retest reproducibility (n=27) ranged from 0.72 (Body Image) to 0.94 (Eating Problems). Patients starting treatment (n=35) had statistically significant increases in scores for NTM Symptoms (+5, p=0.04), Digestive Symptoms (+7, p=0.002), Body Image (+7, p=0.03) and QOL-B Respiratory Symptoms (n=25, +10, p=0.006). NTM Symptoms scores increased by 15 points (p=0.002) in the 16 patients with scores ≤80 at enrolment.Conclusion The NTM Module generally performs well as a valid patient-reported outcome for pulmonary MAC disease and was responsive to MAC treatment.The NTM Symptom Module is a valid patient-reported outcome tool that can facilitate patient-centred care and may be used as an outcome in clinical trials to support labelling claims for regulatory bodies. http://bit.ly/2nwlPgi ER -